Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins

Plasma cell leukemia

(2011) Flavio Albarracin et al.   BLOOD REVIEWS

Genomics in Multiple Myeloma

(2011) Nikhil C. Munshi et al.   CLINICAL CANCER RESEARCH

Measles Virus Glycoprotein-Pseudotyped Lentiviral Vector-Mediated Gene Transfer into Quiescent Lymphocytes Requires Binding to both SLAM and CD46 Entry Receptors

(2011) C. Frecha et al.   JOURNAL OF VIROLOGY

Multiple Myeloma

(2010) Jacob Laubach et al.   Annual Review of Medicine

Lentiviral vectors and transduction of human cancer B cells

(2010) C. Levy et al.   BLOOD

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

(2010) Andrea Di Bernardo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

(2010) J. Moreaux et al.   HAEMATOLOGICA

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

(2010) D. Hose et al.   HAEMATOLOGICA

Memory B and memory plasma cells

(2010) Taketoshi Yoshida et al.   IMMUNOLOGICAL REVIEWS

Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collection

(2010) Anouk Caraux et al.   IMMUNOLOGY

An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization

(2009) M. Jourdan et al.   BLOOD

Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors

(2009) C. Frecha et al.   BLOOD

Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells

(2009) H.-D. Hummel et al.   JOURNAL OF GENERAL VIROLOGY

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone

(2008) F. Zhan et al.   BLOOD

Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins

(2008) C. Frecha et al.   BLOOD

Oncolytic virotherapy for multiple myeloma

(2008) Amaalia E Stief et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome

(2008) Olivier Decaux et al.   JOURNAL OF CLINICAL ONCOLOGY